List of Tables
Table 1. Oligonucleotide-based Therapies Market Trends
Table 2. Oligonucleotide-based Therapies Market Drivers & Opportunity
Table 3. Oligonucleotide-based Therapies Market Challenges
Table 4. Oligonucleotide-based Therapies Market Restraints
Table 5. Global Oligonucleotide-based Therapies Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Oligonucleotide-based Therapies Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Oligonucleotide-based Therapies Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Oligonucleotide-based Therapies Product Type
Table 9. Key Companies Time to Begin Mass Production of Oligonucleotide-based Therapies
Table 10. Global Oligonucleotide-based Therapies Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide-based Therapies as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Oligonucleotide-based Therapies Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Oligonucleotide-based Therapies Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Oligonucleotide-based Therapies Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Oligonucleotide-based Therapies Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Oligonucleotide-based Therapies Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Oligonucleotide-based Therapies Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Oligonucleotide-based Therapies Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Oligonucleotide-based Therapies Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Oligonucleotide-based Therapies Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Oligonucleotide-based Therapies Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Oligonucleotide-based Therapies Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Oligonucleotide-based Therapies Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Oligonucleotide-based Therapies Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Oligonucleotide-based Therapies Sales Value by Region (2019-2024) & (%)
Table 27. Global Oligonucleotide-based Therapies Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Oligonucleotide-based Therapies Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Oligonucleotide-based Therapies Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Oligonucleotide-based Therapies Sales Value, (2025-2030) & (US$ Million)
Table 31. Biogen Basic Information List
Table 32. Biogen Description and Business Overview
Table 33. Biogen Oligonucleotide-based Therapies Products, Services and Solutions
Table 34. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Biogen (2019-2024)
Table 35. Biogen Recent Developments
Table 36. Sarepta Therapeutics Basic Information List
Table 37. Sarepta Therapeutics Description and Business Overview
Table 38. Sarepta Therapeutics Oligonucleotide-based Therapies Products, Services and Solutions
Table 39. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Sarepta Therapeutics (2019-2024)
Table 40. Sarepta Therapeutics Recent Developments
Table 41. Jazz Pharmaceuticals Basic Information List
Table 42. Jazz Pharmaceuticals Description and Business Overview
Table 43. Jazz Pharmaceuticals Oligonucleotide-based Therapies Products, Services and Solutions
Table 44. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Jazz Pharmaceuticals (2019-2024)
Table 45. Jazz Pharmaceuticals Recent Developments
Table 46. Bausch & Lomb Basic Information List
Table 47. Bausch & Lomb Description and Business Overview
Table 48. Bausch & Lomb Oligonucleotide-based Therapies Products, Services and Solutions
Table 49. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Bausch & Lomb (2019-2024)
Table 50. Bausch & Lomb Recent Developments
Table 51. Alnylam Pharmaceuticals Basic Information List
Table 52. Alnylam Pharmaceuticals Description and Business Overview
Table 53. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Products, Services and Solutions
Table 54. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Alnylam Pharmaceuticals (2019-2024)
Table 55. Alnylam Pharmaceuticals Recent Developments
Table 56. Dynavax Technologies Basic Information List
Table 57. Dynavax Technologies Description and Business Overview
Table 58. Dynavax Technologies Oligonucleotide-based Therapies Products, Services and Solutions
Table 59. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Dynavax Technologies (2019-2024)
Table 60. Dynavax Technologies Recent Developments
Table 61. Kastle therapeutics Basic Information List
Table 62. Kastle therapeutics Description and Business Overview
Table 63. Kastle therapeutics Oligonucleotide-based Therapies Products, Services and Solutions
Table 64. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Kastle therapeutics (2019-2024)
Table 65. Kastle therapeutics Recent Developments
Table 66. Akcea Therapeutics Basic Information List
Table 67. Akcea Therapeutics Description and Business Overview
Table 68. Akcea Therapeutics Oligonucleotide-based Therapies Products, Services and Solutions
Table 69. Revenue (US$ Million) in Oligonucleotide-based Therapies Business of Akcea Therapeutics (2019-2024)
Table 70. Akcea Therapeutics Recent Developments
Table 71. Key Raw Materials Lists
Table 72. Raw Materials Key Suppliers Lists
Table 73. Oligonucleotide-based Therapies Downstream Customers
Table 74. Oligonucleotide-based Therapies Distributors List
Table 75. Research Programs/Design for This Report
Table 76. Key Data Information from Secondary Sources
Table 77. Key Data Information from Primary Sources
Table 78. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Oligonucleotide-based Therapies Product Picture
Figure 2. Global Oligonucleotide-based Therapies Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 4. Oligonucleotide-based Therapies Report Years Considered
Figure 5. Global Oligonucleotide-based Therapies Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oligonucleotide-based Therapies Revenue in 2023
Figure 7. Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Antisense Oligonucleotide Picture
Figure 9. Aptamer Picture
Figure 10. Other Picture
Figure 11. Global Oligonucleotide-based Therapies Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Oligonucleotide-based Therapies Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Neuromuscular Diseases
Figure 14. Product Picture of Hepatic VOD
Figure 15. Product Picture of Other
Figure 16. Global Oligonucleotide-based Therapies Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Oligonucleotide-based Therapies Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Oligonucleotide-based Therapies Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Oligonucleotide-based Therapies Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Oligonucleotide-based Therapies Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Oligonucleotide-based Therapies Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Oligonucleotide-based Therapies Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Oligonucleotide-based Therapies Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Oligonucleotide-based Therapies Sales Value (%), (2019-2030)
Figure 29. United States Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 35. China Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 37. China Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 47. India Oligonucleotide-based Therapies Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Oligonucleotide-based Therapies Sales Value by Type (%), 2023 VS 2030
Figure 49. India Oligonucleotide-based Therapies Sales Value by Application (%), 2023 VS 2030
Figure 50. Oligonucleotide-based Therapies Industrial Chain
Figure 51. Oligonucleotide-based Therapies Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
